Evolutionary Genomics, Inc. Stock
Stocks
FNAM
US30051F1012
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
17:21:23 31/10/2025 +03
|
5-day change | 1st Jan Change | ||
| 0.000200 USD | -.--% |
|
-.--% | - |
| 09/03/23 | Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 09/03/23 | Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 2.99M 2.67M 2.47M 2.24M 4.21M 283M 4.26M 29.62M 11.62M 149M 11.23M 11M 473M | P/E 2021 |
-1.34x | P/E 2022 | -2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.16M 5.49M 5.08M 4.6M 8.67M 581M 8.77M 60.95M 23.91M 306M 23.11M 22.63M 974M | EV / Sales 2021 |
-
| EV / Sales 2022 | - |
| Free-Float |
67.35% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0 | |
| 5 years | 0 | 0.9 | |
| 10 years | 0 | 5.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Walter Messier
CTO | Chief Tech/Sci/R&D Officer | 71 | 01/01/2000 |
Steve Warnecke
CEO | Chief Executive Officer | 70 | 01/10/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Warnecke
CHM | Chairman | 70 | 01/10/2014 |
| Director/Board Member | 76 | 01/01/2000 | |
Mark Boggess
BRD | Director/Board Member | 66 | 01/01/2010 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/23/22 A | Exercice | Chief Executive Officer | 185,715 | 2.8074% | ||
| 5/23/22 A | Exercice | Founder | 278,571 | 4.2111% | ||
| 5/23/22 A | Exercice | Founder | 55,714 | 0.8422% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -99.96% | 1.33K | ||
| -0.21% | -4.43% | +44.40% | +74.13% | 66.22B | ||
| -3.59% | -0.11% | +6.85% | +68.06% | 55.2B | ||
| +0.11% | +3.28% | +11.36% | +90.35% | 52.79B | ||
| +3.28% | +5.58% | +26.51% | +50.05% | 45.53B | ||
| +0.51% | +9.95% | +22.40% | +133.92% | 43.94B | ||
| -1.15% | +0.39% | +263.21% | +594.60% | 41.64B | ||
| +0.10% | +9.90% | +16.11% | +59.33% | 34B | ||
| -8.38% | -6.95% | +26.35% | -1.93% | 25.84B | ||
| -0.73% | +2.65% | +35.21% | +25.23% | 23.51B | ||
| Average | -1.02% | +3.67% | +45.24% | +99.38% | 38.87B | |
| Weighted average by Cap. | -0.82% | +3.72% | +49.21% | +125.86% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.79M -2.49M -2.31M -2.09M -3.93M -264M -3.98M -27.64M -10.84M -139M -10.48M -10.26M -442M | -1.93M -1.72M -1.6M -1.44M -2.72M -183M -2.75M -19.14M -7.51M -95.98M -7.26M -7.11M -306M |
| Net Debt | 3.53M 3.15M 2.91M 2.64M 4.97M 333M 5.02M 34.92M 13.7M 175M 13.24M 12.97M 558M | 3.17M 2.82M 2.61M 2.36M 4.45M 299M 4.51M 31.32M 12.29M 157M 11.88M 11.63M 501M |
Employees
3
- Stock Market
- Stocks
- FNAM Stock
Select your edition
All financial news and data tailored to specific country editions
















